Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells.
about
TLR7/TLR8 Activation Restores Defective Cytokine Secretion by Myeloid Dendritic Cells but Not by Plasmacytoid Dendritic Cells in HIV-Infected Pregnant Women and NewbornsInnate Immunity and Immune Evasion by Enterovirus 71Ontogeny of early life immunityMessenger RNA-based vaccines: progress, challenges, applicationsCellular and molecular mechanisms underlying the strong neonatal IL-12 response of lamb mesenteric lymph node cells to R-848Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infantsThe rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategiesMaturation of innate responses to mycobacteria over the first nine months of life.Role of innate host defenses in susceptibility to early-onset neonatal sepsis.Development of newborn and infant vaccinesYersinia enterocolitica promotes robust mucosal inflammatory T-cell immunity in murine neonatesAn alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal miceThe challenge of assessing infant vaccine responses in resource-poor settingsHuman Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-aminesSoluble mediators regulating immunity in early lifeDecreased Toll-like receptor 8 expression and lower TNF-α synthesis in infants with acute RSV infectionProfound lack of interleukin (IL)-12/IL-23p40 in neonates born early in gestation is associated with an increased risk of sepsis.Ontogeny of Toll-like and NOD-like receptor-mediated innate immune responses in Papua New Guinean infantsToll-like receptor 2 agonists inhibit human fibrocyte differentiation.The difference in immune response and IL-12p35 methylation between newborns and adults.The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.Trained immunity in newborn infants of HBV-infected mothersImmunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic miceToll-like receptor 1/2 stimulation induces elevated interleukin-8 secretion in polymorphonuclear leukocytes isolated from preterm and term newborn infantsMHC class I/peptide transfer between dendritic cells overcomes poor cross-presentation by monocyte-derived APCs that engulf dying cellsMurine neonates are highly resistant to Yersinia enterocolitica following orogastric exposure.Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factorsNeonatal innate TLR-mediated responses are distinct from those of adults.Hierarchical maturation of innate immune defences in very preterm neonates.Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolinesDendritic cells differentiated in the presence of a single-stranded viral RNA sequence conserve their ability to activate CD4 T lymphocytes but lose their capacity for Th1 polarizationDefective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists.In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant.Malaria modifies neonatal and early-life toll-like receptor cytokine responses.TLR7 and TLR8 as targets in cancer therapy.Direct TLR-2 Costimulation Unmasks the Proinflammatory Potential of Neonatal CD4+ T Cells.Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis.Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.Safety and efficacy of neonatal vaccination.
P2860
Q24297513-5EF54011-76DE-4EF2-A8A6-7B12E014013FQ26773329-354E7495-8E34-4C43-9683-8576E47475E2Q27000632-0F0807DD-D9C3-4A91-8321-ABC5334EC247Q27012738-55563BCE-B8FA-4AF3-B433-769486AD4BBCQ28475947-5A9EBF3D-680C-4869-B348-BF73D0FAF302Q28741059-7EFD3BF1-A7D2-4B09-818E-04AC0A821B8BQ30374404-1DFBE51A-48B5-4A0C-8423-8874190226F6Q33723428-BE5AA4AE-D3BD-4F7D-8E2A-8D8B39CE3566Q33940417-CD33034F-C3A4-433C-A36F-2F0F70BAE89BQ33941914-56C6C02B-0C64-4FA0-991B-0B7FEFB72B82Q34045124-680D8085-528E-45AD-8698-9836F0153E2BQ34059308-1702ECE0-7C26-46A2-A1EA-700C67FFB3AFQ34118427-4336CDE5-3302-4A8F-BE5B-A6410D90383AQ34164851-C2CB9002-C105-473D-8CFD-08BBB3946743Q34238426-2B616C59-3035-4D65-9647-6A09502226EAQ34282702-79C4263B-3E1C-44E2-8DE3-EFFBDA812CAEQ34286789-EB4CA044-2345-4128-B2C8-03392CDB9621Q34287383-7612C994-4040-4999-B511-BD28D2BD5164Q34408050-43CE38F3-F8B5-4BEC-9C8F-A1A1B2974FF8Q34544444-D6FDE390-563F-4B1A-9951-D6BA7177A731Q34618662-79E84CE0-94A8-41C0-B1D5-EE5484D2D779Q35311846-382455AE-9C6E-418C-8ECC-18B427B9CA84Q35424070-09BC6B64-DB5B-448B-B6B3-354E4E0886F2Q35570164-EA0C35C4-6468-4036-922E-4E3FCAB43299Q35751117-69738CB0-CFDD-4FCE-88D9-3FFE4997E43AQ35783987-3BB85E82-8FC0-403C-8C04-E2E3AE857E5AQ35839858-2417DCAC-B964-4C2D-B978-859052C377C0Q36015806-5E0422A1-FFF3-4E8C-8D00-B301EBDB347CQ36016382-2048CEA4-8AB8-43DA-92E8-BA1C62DFC2B6Q36069620-F92F9D9C-E0ED-4A88-9115-5ABBBA848239Q36625137-21A6DADA-E30B-4A12-A3C7-996A67ECF267Q36746891-3D6BF833-38EE-4112-99BD-7FB164CF6643Q36843705-75DD82CF-66F9-4094-A15A-F378E5E07933Q37001755-F6E8C031-C67B-4998-9EC9-1161E68D9D8CQ37036029-6C6D8746-7DCB-49CA-84B9-D2C854D15335Q37051014-58B13206-3361-4906-9078-C20A8525A3CCQ37255692-49346939-732E-4778-8685-C6AC80B5B58DQ37260284-C0FA94FC-9B9C-4FD7-8D85-26863CCB2A18Q37282316-EAEEE4CA-B696-46EC-A64A-F32F536D37B2Q37336304-E5313701-F1F5-4760-BD78-EC93AB84A0D3
P2860
Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Unique efficacy of Toll-like r ...... atal antigen-presenting cells.
@ast
Unique efficacy of Toll-like r ...... atal antigen-presenting cells.
@en
type
label
Unique efficacy of Toll-like r ...... atal antigen-presenting cells.
@ast
Unique efficacy of Toll-like r ...... atal antigen-presenting cells.
@en
prefLabel
Unique efficacy of Toll-like r ...... atal antigen-presenting cells.
@ast
Unique efficacy of Toll-like r ...... atal antigen-presenting cells.
@en
P2093
P2860
P1433
P1476
Unique efficacy of Toll-like r ...... atal antigen-presenting cells.
@en
P2093
Eugénie E Suter
Michael R Wessels
Richard L Miller
P2860
P304
P356
10.1182/BLOOD-2005-12-4821
P407
P577
2006-04-25T00:00:00Z